[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AUPP345098A0 - Novel anti-fibrinolytic agents - Google Patents

Novel anti-fibrinolytic agents

Info

Publication number
AUPP345098A0
AUPP345098A0 AUPP3450A AUPP345098A AUPP345098A0 AU PP345098 A0 AUPP345098 A0 AU PP345098A0 AU PP3450 A AUPP3450 A AU PP3450A AU PP345098 A AUPP345098 A AU PP345098A AU PP345098 A0 AUPP345098 A0 AU PP345098A0
Authority
AU
Australia
Prior art keywords
inhibitors
novel anti
plasmin
fibrinolytic agents
textilis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP3450A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
National Institute for Biological Standards and Control
Original Assignee
NAT INST OF BIOLOG STANDARDS A
University of Queensland UQ
National Institute for Biological Standards and Control
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAT INST OF BIOLOG STANDARDS A, University of Queensland UQ, National Institute for Biological Standards and Control filed Critical NAT INST OF BIOLOG STANDARDS A
Priority to AUPP3450A priority Critical patent/AUPP345098A0/en
Publication of AUPP345098A0 publication Critical patent/AUPP345098A0/en
Priority to PCT/AU1999/000343 priority patent/WO1999058569A1/en
Priority to DK99918966T priority patent/DK1078003T3/en
Priority to AU36922/99A priority patent/AU759190B2/en
Priority to US09/700,179 priority patent/US7070969B1/en
Priority to DE69941292T priority patent/DE69941292D1/en
Priority to AT99918966T priority patent/ATE440108T1/en
Priority to ES99918966T priority patent/ES2332249T3/en
Priority to NZ508770A priority patent/NZ508770A/en
Priority to JP2000548371A priority patent/JP4542705B2/en
Priority to CA2328431A priority patent/CA2328431C/en
Priority to EP99918966A priority patent/EP1078003B1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention provides novel single stage competitive inhibitors of plasmin from the Australian brown snake Pseudonaja textilis textilis. The invention also features polynucleotides and polynucleotide homologues encoding these inhibitors. Pharmaceutical compositions containing the plasmin inhibitors of the invention are also disclosed as well as methods useful for treatment of blood loss.
AUPP3450A 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents Abandoned AUPP345098A0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents
EP99918966A EP1078003B1 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake, pseudonaja textilis textilis
US09/700,179 US7070969B1 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis
DK99918966T DK1078003T3 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the Australian brown snake, pseudonaja textilis textilis
AU36922/99A AU759190B2 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the Australian brown snake (Pseudonaja textilis textilis)
PCT/AU1999/000343 WO1999058569A1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)
DE69941292T DE69941292D1 (en) 1998-05-11 1999-05-07 SNAKE, PSEUDONAJA TEXTILIS TEXTILIS
AT99918966T ATE440108T1 (en) 1998-05-11 1999-05-07 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE, PSEUDONAJA TEXTILIS TEXTILIS
ES99918966T ES2332249T3 (en) 1998-05-11 1999-05-07 PLASMINE INHIBITORS OF AUSTRALIAN BROWN SNAKE, PSEUDONAJA TEXTILIS TEXTILIS.
NZ508770A NZ508770A (en) 1998-05-11 1999-05-07 Textilinin plasmin inhibitors from the Australian brown snake pseudonaja textilis textilis
JP2000548371A JP4542705B2 (en) 1998-05-11 1999-05-07 Plasmin inhibitors from Australian Brown Snake, Pseudonaja Textiles Textiles
CA2328431A CA2328431C (en) 1998-05-11 1999-05-07 Plasmin inhibitors from the australian brown snake pseudonaja textilis textilis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP3450A AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents

Publications (1)

Publication Number Publication Date
AUPP345098A0 true AUPP345098A0 (en) 1998-06-04

Family

ID=3807704

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP3450A Abandoned AUPP345098A0 (en) 1998-05-11 1998-05-11 Novel anti-fibrinolytic agents

Country Status (11)

Country Link
US (1) US7070969B1 (en)
EP (1) EP1078003B1 (en)
JP (1) JP4542705B2 (en)
AT (1) ATE440108T1 (en)
AU (1) AUPP345098A0 (en)
CA (1) CA2328431C (en)
DE (1) DE69941292D1 (en)
DK (1) DK1078003T3 (en)
ES (1) ES2332249T3 (en)
NZ (1) NZ508770A (en)
WO (1) WO1999058569A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents
US6506365B1 (en) * 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
US7745192B2 (en) * 2002-04-03 2010-06-29 Venomics Pty Limited Prothrombin activating protein
ES2431526T3 (en) 2005-12-29 2013-11-26 The Regents Of The University Of California Office Of Technology Transfer Procedures and compositions related to the Kunitz I mutant domain of TFPI-2
EP2154152A1 (en) * 2008-08-08 2010-02-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of Conkunitzin-S1 for the modulation of glucose-induced insulin secretion
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
CN102850451B (en) * 2011-06-29 2014-05-07 辽宁诺康生物制药有限责任公司 Recombinant textilinin-1 with plasmin inhibition activity, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
EP0585504A1 (en) * 1992-09-04 1994-03-09 Pentapharm A.G. Phospholipid dependant prothrombin activator and its use in lupus anticoagulant testing
AUPP076797A0 (en) * 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
AUPP345098A0 (en) * 1998-05-11 1998-06-04 National Institute Of Biological Standards And Control, United Kingdom Novel anti-fibrinolytic agents

Also Published As

Publication number Publication date
EP1078003A4 (en) 2004-08-25
CA2328431C (en) 2010-04-27
WO1999058569A1 (en) 1999-11-18
EP1078003B1 (en) 2009-08-19
DK1078003T3 (en) 2009-12-07
NZ508770A (en) 2003-12-19
US7070969B1 (en) 2006-07-04
EP1078003A1 (en) 2001-02-28
JP2002514404A (en) 2002-05-21
DE69941292D1 (en) 2009-10-01
CA2328431A1 (en) 1999-11-18
ATE440108T1 (en) 2009-09-15
JP4542705B2 (en) 2010-09-15
ES2332249T3 (en) 2010-01-29

Similar Documents

Publication Publication Date Title
BR9908280A (en) Phospholipase enzyme inhibitors
DE69905476D1 (en) Phosphonsaürederivate als ptp-1b-inhibitoren
IL132797A0 (en) Compounds and methods for the inhibition of the expression of vcam-1
MXPA03004832A (en) Compounds and their uses.
BR0013200A (en) Compounds derived from nitrogen containing heterobicycles, pharmaceutical compositions, method of treatment or prevention of thromboembolic dysfunction and use of the compounds
WO2000066104A3 (en) Ace-2 inhibiting compounds and methods of use thereof
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
HRP20020330B1 (en)
WO2004032908A3 (en) Method of inhibiting angiogenesis
IL143384A0 (en) New amidino derivatives and their use as thrombin inhibitors
MXPA03001536A (en) Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same.
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
AUPP345098A0 (en) Novel anti-fibrinolytic agents
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
TR200200278T2 (en) Calcilitic compositions
IL139144A0 (en) Mycobacterial inhibitors
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
PT1276722E (en) NAFTAMIDINE-UROQUINASE INHIBITORS
MXPA03010259A (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof.
EP1436279A4 (en) Chemical compounds
WO2001035951A3 (en) Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
MXPA03001986A (en) Antithrombotic compositions.
ES2122912A1 (en) Metalocarboxypeptidase inhibitors and derived molecules used as antitumor agents
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
PT1144348E (en) LTA INHIBITORS, HYDROLASE